Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma
Status:
Unknown status
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
Esophageal or esophageal-gastric junction squamous cell cancer has dismal prognosis. And
still no promising chemotherapeutic drugs is existed. In this study, The investigators wanted
to look at the effects and safety of first line docetaxel-PM and oxaliplatin weekly
administration chemotherapy for the participants with inoperable or metastatic esophageal
squamous cell carcinoma.